Market Performance - The Sci-Tech 50 Index opened slightly higher on January 26 but experienced a significant drop after an initial rise, closing down by 1.35% at 1532.80 points with a total trading volume of approximately 108.9 billion yuan, a slight decrease from the previous trading day [1] - The Sci-Tech Comprehensive Index also opened slightly higher but fell sharply, closing down by 2.23% at 1857.50 points, with a total trading volume of about 344.9 billion yuan, which was an increase compared to the previous trading day [1] Stock Performance - Among the stocks listed on the Sci-Tech board, 109 stocks rose, accounting for approximately 18.17% of the total, while the majority experienced declines [1] - Notable gainers included Zhijiang Biology, Yike De, Ruihua Tai, and Jindike, which all reached a limit-up of around 20% [2] - In contrast, Xinke Mobile saw the largest decline, dropping by 18.15% [2] Trading Metrics - The average decline for the 600 stocks on the Sci-Tech board was 2.12%, with an average turnover rate of 4.20% and a total trading volume of 344.9 billion yuan, reflecting an average fluctuation of 5.96% [1] - Lanqi Technology had the highest trading volume at 11.289 billion yuan, while ST Pava recorded the lowest at 951.73 million yuan [3] - Yike De led in turnover rate at 30.41%, while Bairen Medical had the lowest turnover rate at 0.22% [4]

Group 1 - The core viewpoint of the news is that Capbio (凯普生物) experienced a significant stock price increase, reaching a limit up of 20.03% on January 26, 2026, with a total market capitalization of 4.687 billion yuan [1] - Capbio has recently announced the acquisition of multiple domestic and international patent authorizations, enhancing its technological barriers and core competitiveness [2] - The actual controller, Ms. Wang Jianyu, has completed an increase in holdings amounting to 18.12 million yuan and plans to continue increasing her stake, signaling confidence in the company's development [2] - The company has expanded its business scope by obtaining production qualifications for Class III in vitro diagnostic reagents and Class II obstetric and gynecological instruments [2] - For the first three quarters of 2025, Capbio reported a narrowing of net losses attributable to shareholders by 51.25%, with operating cash flow increasing by 173.06% to 121 million yuan, indicating an improvement in operational conditions [2] - Capbio, as an integrated supplier of molecular diagnostic products and services, is expected to benefit from the growth in the in vitro diagnostics sector within the biopharmaceutical industry [2] - On the market performance side, the biopharmaceutical sector saw active movements, with Capbio's limit-up creating a certain sector linkage effect [2] - Technical indicators such as the MACD forming a golden cross and breaking through the upper Bollinger Band may attract more capital attention [2] - There was likely a flow of main funds into the stock, contributing to the price surge [2]

Summary of Expert Call on China's IVD Market Industry Overview - **Industry**: In-vitro diagnostics (IVD) market in China - **Expert**: Mr. Fang, an IVD distributor with over 15 years of experience Key Points Market Size and Growth Trends - **Q425 Market Performance**: - **Chemiluminescent immunoassay (CLIA)**: -12% YoY in test volume and -16% YoY in revenue, but showed QoQ recovery as panel test unbundling policies ended [2][8] - **Clinical Chemistry**: -5% YoY in both volume and revenue, with volume-based procurement (VBP) largely completed [2][8] - **Haematology**: +6% YoY in both volume and revenue, driven by high influenza A incidence [2][8] - **Haemostasis**: +5% YoY in both volume and revenue [2][8] - **Molecular Testing**: +9% YoY in revenue, also supported by influenza A [2][9] - **Point of Care Tests (POCT)**: -11% YoY in both volume and revenue, due to a shift to CLIA and suspension of non-compliant prescriptions [2][9] Competitive Landscape - **Channel Inventory**: - CLIA: Global brands have 3 months of sales in inventory, down 2 weeks from Q325; domestic brands have 6-10 weeks [3][14] - Haematology: Mindray and Sysmex have 14 weeks and 5 months of sales in inventory, respectively, expected to reduce in 2026 [3][17] - **Import Substitution**: - Significant gains for domestic companies like Mindray in CLIA and haemostasis, while overseas companies like Roche and Siemens lost market share [3][12][28] 2026 Market Outlook - **Growth Projections**: - **CLIA**: Expected to shrink by 2% YoY despite a 2-3% increase in test volume [4][19] - **Clinical Chemistry**: Anticipated growth of 2% YoY [4][20] - **Haematology**: Expected growth of 5% YoY, assuming no national policy headwinds [4][21] - **Haemostasis**: Expected growth of 6% YoY [4][22] - **Molecular Testing**: Expected growth of 7% YoY [4][23] - **POCT**: Expected decline of 6% YoY [4][24] Policy Impacts - **Testing Fee Unification**: Seen as a major swing factor for market growth in 2026, with potential price cuts of 30-40% for reagents not covered by VBPs [4][35][37] - **VBP Implementation**: Five provinces have initiated VBP programs, with full implementation expected by Q126 [29] Risks and Considerations - **Market Risks**: - Potential for larger-than-expected price reductions and smaller market share gains from VBP programs [40] - Weaker demand from equipment renewal programs and geopolitical issues affecting supply chains [40] Additional Insights - The expert noted that the impact of the Chinese New Year on sales growth was about 5-6% YoY due to later occurrence in 2026 compared to 2025 [7] - The expert expressed a more positive outlook for CLIA in 2026 compared to previous estimates, reflecting recent QoQ recovery [4][24] This summary encapsulates the key insights from the expert call regarding the current state and future outlook of China's IVD market, highlighting growth trends, competitive dynamics, and the impact of policy changes.

Group 1 - The company, Hefei China, expects a net profit loss of between 25 million to 36 million yuan for 2025, compared to a net profit of 27.57 million yuan in the same period last year. The expected non-net profit loss is between 24 million to 35 million yuan [2] - The company's consolidated operating revenue for 2025 is projected to be 689 million yuan, a decrease of 26.67% compared to the previous year [2] - The anticipated losses are attributed to changes in the domestic macro environment and the impact of centralized procurement policies in the in vitro diagnostics industry, leading to reduced product procurement prices and fluctuations in order volumes [2] Group 2 - To address market and business changes, the company is actively adjusting its business layout and development strategy, focusing on the technological iteration and innovation of its "ACME" proprietary products, increasing R&D investment, and expanding its market development team [3] - The company signed a long-term procurement agreement with Nanjing Mingji Hospital and Suzhou Mingji Hospital, committing to a total procurement amount of no less than 600 million yuan over 96 months for in vitro diagnostic reagents and consumables [3] - This contract is expected to positively impact the company's performance in 2026 and beyond, enhancing its sustainable profitability and overall competitiveness [3] Group 3 - The company has indicated that if the procurement prices for in vitro diagnostic reagents and consumables are adjusted during the contract period, the supply prices will also be adjusted proportionally [4] - The contract is a routine operational contract with a long performance period, and the annual procurement amount from Mingji Hospital is expected to be less than 10% of the company's annual revenue, minimizing dependency on this single client [4]

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics industry [4][54]. Core Views - The in vitro diagnostics industry is stabilizing due to policy and technological advancements, including the accelerated integration of AI in diagnostics, the implementation of price reforms, and the stabilization of centralized procurement impacts [4][54]. - The report highlights the importance of focusing on specific growth areas within the industry, such as chemiluminescence in immunodiagnostics and PCR in molecular diagnostics, with companies like YHLO and Shengxiang Bio being recommended for attention [4][54]. Summary by Sections Industry Performance - The pharmaceutical and biological sector decreased by 0.39%, while the in vitro diagnostics sector increased by 0.42% during the week [1][20]. - The in vitro diagnostics sector's PE ratio is currently at 40.90X, with a recent increase of 0.17X, and the PB ratio is at 1.87X, up by 0.01X from the previous week [3][30]. Key Developments - AI diagnostics are evolving from auxiliary tools to core components of clinical processes, enhancing diagnostic efficiency and driving industry modernization [4][54]. - The Chongqing Medical Insurance Bureau has introduced a price reform draft for pathological services, which is expected to enhance the value recognition of diagnostic services [4][54]. - The impact of centralized procurement is stabilizing, with price pressures gradually easing and testing volumes expected to stabilize following the unbundling of service packages [4][54]. Company Performance - Notable companies in the medical services sector include Aotai Bio (+7.9%), Saikexide (+4.5%), and Mingde Bio (+4.0%), while underperformers include Rejing Bio (-8.7%) and Botuo Bio (-3.3%) [2][25]. - The report suggests that the domestic biochemical diagnostics sector has largely overcome foreign constraints, indicating a completed localization process [4][54].

Core Viewpoint - Company expects a net profit loss of 24 million to 35 million yuan for the full year of 2025 due to various challenges in the market and operational adjustments [1] Group 1: Performance Forecast - Company anticipates a net profit loss of 24 million to 35 million yuan for 2025 after deducting non-recurring items [1] - The decline in profit is attributed to changes in the macro environment and the impact of centralized procurement policies in the in-vitro diagnostics industry [2] Group 2: Reasons for Performance Changes - The competitive landscape is being reshaped, leading to decreased product procurement prices from hospital clients and fluctuations in order volumes, which pose challenges to sales revenue and gross profit levels [2] - Despite cost-saving measures, fixed expenditures cannot be reduced proportionally to income, and investments in talent optimization and capability upgrades have contributed to the expected losses [2] - The company is actively adjusting its business layout and development strategy, focusing on the technological iteration and innovation of its proprietary "ACME" products, increasing R&D investment, and expanding the market development team [2] Group 3: Financial Performance - For the first three quarters of 2025, the company's main revenue was 549 million yuan, a year-on-year decrease of 22.8% [3] - The net profit attributable to the parent company was -12.39 million yuan, a year-on-year decline of 146.65% [3] - The gross profit margin stood at 15.84%, with a debt ratio of 27.18% [3]

Core Viewpoint - Company expects a net profit loss of 25 million to 36 million yuan for the full year of 2025 due to various challenges in the market and operational adjustments [1] Group 1: Performance Forecast - Company anticipates a net profit loss of 25 million to 36 million yuan for 2025 [1] - The forecasted loss is attributed to changes in the macro environment and the impact of centralized procurement policies in the in-vitro diagnostics industry [2] Group 2: Reasons for Performance Changes - The competitive landscape is being reshaped, leading to a decrease in product procurement prices and fluctuations in order volumes, which pose challenges to sales revenue and gross margin [2] - Despite cost-saving measures, fixed expenditures remain constant, and investments in talent optimization and capability upgrades have contributed to the expected losses [2] - The company is adjusting its business layout and strategy, focusing on the "ACME" proprietary products, increasing R&D investment, and expanding the market development team to enhance high-value services for hospital clients [2] Group 3: Financial Performance - For the first three quarters of 2025, the company's main revenue was 549 million yuan, a year-on-year decrease of 22.8% [3] - The net profit attributable to shareholders was -12.39 million yuan, a decline of 146.65% year-on-year [3] - The gross margin was reported at 15.84%, with a debt ratio of 27.18% [3]

Core Viewpoint - The company, Hefei China, anticipates a net profit loss of between 36 million yuan and 25 million yuan for the year 2025, indicating a significant decline compared to the previous year [1] Company Performance - The projected loss is attributed to changes in the domestic macro environment and the implementation of centralized procurement policies in the in vitro diagnostic industry, which are reshaping the market competition landscape [1] - The company has experienced a decrease in product procurement prices from hospital clients, leading to fluctuations in order volume compared to the previous year, which poses challenges to sales revenue and gross profit levels [1] Cost Management and Strategic Initiatives - Despite implementing various cost-saving and expense control measures, the company faces fixed expenditures that cannot be proportionately reduced alongside revenue [1] - The company has invested in optimizing its talent structure and building a core talent team to capitalize on opportunities created since the launch of the ACME strategy, resulting in costs related to personnel optimization and capability upgrades [1]

Core Viewpoint - Company expects a net loss attributable to shareholders of 25 million to 36 million yuan for the year 2025, compared to a net profit of 27.5663 million yuan in the same period last year, indicating a significant downturn due to changes in the macro environment and industry policies [1] Group 1: Financial Performance - The anticipated net loss for 2025 reflects the impact of changes in the domestic macro environment and the implementation of centralized procurement policies in the in-vitro diagnostics industry, which have led to a reshaping of the market competition landscape [1] - The company's sales revenue and gross profit levels are facing temporary challenges due to fluctuations in product procurement prices from hospital clients and variations in order volumes compared to the previous year [1] Group 2: Strategic Developments - The company has signed a long-term procurement agreement with Nanjing Mingji Hospital and Suzhou Mingji Hospital, committing to supply in-vitro diagnostic reagents and consumables, along with comprehensive services [1] - The total procurement amount from Mingji Hospital is expected to be no less than 600 million yuan over a period of 96 months, which, if executed successfully, is projected to have a positive impact on the company's performance in 2026 and subsequent years [1]

Core Viewpoint - The company, Hefei China, anticipates a significant net loss for the year 2025, with projected losses ranging from 25 million to 36 million yuan for net profit attributable to shareholders, and from 24 million to 35 million yuan for net profit after excluding non-recurring gains and losses [1] Group 1: Financial Performance - The expected net loss for 2025 is between 25 million and 36 million yuan [1] - The projected net profit after excluding non-recurring items is estimated to be between 24 million and 35 million yuan [1] Group 2: Reasons for Performance - The primary reasons for the anticipated losses include changes in the domestic macro environment and the impact of centralized procurement policies in the in-vitro diagnostic industry, leading to decreased product procurement prices and fluctuations in order volumes [1] - Despite cost-saving measures, fixed expenditures could not be proportionately reduced alongside income, and investments in talent optimization and capability upgrades contributed to the expected losses [1] - The company is actively adjusting its business layout and development strategy, focusing on the technological iteration and innovation of its proprietary "ACME" products, increasing R&D investments, and expanding its market development team [1]